Krystal Biotech gets expanded FDA approval for Vyjuvek (KRYS:NASDAQ)

Group 1 - Krystal Biotech announced FDA approval for an updated label for its gene therapy, Vyjuvek (beremagene geperpavec) [6] - The new approval expands patient eligibility to include individuals with dystrophic epidermolysis bullosa from birth [6] - The updated label allows for broader access to the therapy for affected patients [6]